CX3CL1 and scleroderma: Emerging evidence claims that FKN could be expressed in numerous tissues, taking part in the CX3CR1‐positive cell accumulation at sites of inflammation and, as a result, be involved in multiple rheumatic diseases such as RA, SLE, and scleroderma.31